Introduction
Vascular endothelial growth factor (VEGF) is a glycoprotein acting as a specific endothelial mitogen. The VEGF gene family encodes five polypeptide growth factors: VEGF-A, -B, -C, -D and -E (1). VEGF-A can induce vascularization around growing tumor cells, and is overexpressed in prostatic tumors such as benign prostatic hyperplasia and prostate cancer (PCa) (2) . It has been suggested that VEGF expression may be regulated by some tumor suppressor genes, including the PTEN (phosphatase, tensin homologue) gene on chromosome 10q23 (3) . Several investigators found a correlation between circulating levels of VEGF-A and the aggressiveness of PCa, but others reached opposite conclusions (4-6). Moreover, most published studies have analysed the impact of VEGF-A in advanced PCa. The impact of VEGF-A in localized PCa remains therefore to be determined.
In the current study we measured the preoperative plasma levels of VEGF-A in 100 consecutive patients undergoing RP for localized PCa. We also examined the VEGF-A expression in the RP specimens, and analysed the associations between pre-RP VEGF plasma levels, VEGF expression in PCa tissue and established prognostic factors of PCa.
Materials and methods
Patient selection. One hundred consecutive patients undergoing RP for clinically-localized PCa at our institution were prospectively enrolled between June and November 2005. None had received hormone therapy, radiation therapy or chemotherapy before intervention. All patients had undergone pelvic CT scan, endorectal magnetic resonance imaging (MRI) and bone scintigraphy before RP. None had clinical or radiological evidence of lymph node or bone metastases. A bilateral pelvic lymphadenectomy was performed at the time of RP. Clinical and pathological stages of PCa were established according to the 2002 TNM classification.
Assessment of biomarkers (serum PSA and VEGF).
Blood was taken from all patients the day before RP and was collected into two 7-ml glass tubes. One tube was used to measure the different forms of PSA. Total PSA, free PSA and complexed PSA were measured in serum using the Bayer Immuno 1 PSA assay. The other tube was used to measure plasma levels of VEGF-A. VEGF-A was measured using an enzymelinked immunosorbent assay (ELISA). Blood was spun at 2500 g for 10 min; then, the platelet-poor plasma was removed and placed in a 5-ml tube, stored at -80˚C and thawed immediately before testing. VEGF-A levels were determined in duplicate with 100 μl of each sample. According to their amino acid content, 5 isoforms of VEGF-A have been identified, namely VEGF 121, VEGF 145, VEGF 165, VEGF 189 and VEGF 206. The immunoassay that we used (Bender MedSystems, Vienna, Austria) is designed to measure all these isoforms.
Tissue microarrays. Slides from the 100 RP specimens were reviewed and mapped. Tissue microarrays were built using a manual tissue arrayer (Beecher Instruments, Alphelys). Areas representative of the tumor with the highest Gleason score were circled. Duplicate 0.6 mm cores were obtained from the circled areas of tumor and transferred to a recipient paraffin block. Controls were obtained from non-malignant prostatic tissue. The tissue array set consisted of 8 blocks, and included the coordinates of each core and case of origin.
Immunohistochemistry. Immunochemical staining was performed on the section mounted on poly-L-Lysine coated glass slides. Before incubation with primary antibodies, deparaffinized and rehydrated sections were incubated with avidin/ biotin blocker (Vector Laboratories, Burlingame, USA) and Fc receptor blocked by human serum (5%). 
Results
The median plasma level of VEGF-A was 145.5 pg/ml (IQR 55.5-230; range 0-4,100). VEGF-A expression in PCa tissue could be determined in 89 cases. VEGF-A expression in PCa tissue was low in 53 patients, and high in the remaining 36. In patients with a positive staining, VEGF-A was detectable in stromal and in epithelial cells (Fig. 1) .
There was no association between plasma VEGF-A values and patient age (p=0.22), prostate weight (p=0.46), total PSA (p=0.48), free/total PSA (p=0.9) or complexed PSA (p=0.51). Moreover, there was no association between VEGF-A expression in PCa tissue and patient age, prostate weight, different forms of PSA, or plasma VEGF-A (Table I) . Table II shows the plasma levels of VEGF-A according to preoperative and postoperative prognostic factors of PCa. There was no association between the plasma levels of VEGF-A and preoperative tumor characteristics. The plasma levels of VEGF-A were lower in patients with a high Gleason score on RP specimen (p=0.04). However, there was no association between the plasma levels of VEGF-A and pathological stage of PCa (p=0.57) or surgical margin status (p=0.48). Table III shows the expression of VEGF-A in PCa tissue according to preoperative and postoperative tumor characteristics. There was no association between the expression of VEGF-A in PCa tissue and preoperative tumor characteristics. The expression of VEGF-A in PCa tissue was significantly higher in patients with a high Gleason score on RP specimen (p=0.01). Two factors were found to be associated with the pathological stage of PCa: the free/total PSA ratio and the post-operative Gleason score. The median free/total PSA ratio was 14% in patients with a pT2 tumor versus 11.5% in those with a pT3 tumor (p=0.04). The rates of extracapsular disease were 19.2, 50, 56.3 and 83.3% in patients with a Gleason score ≤6 or of 3+4, 4+3 and >7, respectively (p=0.002). Finally, the sole factor associated with surgical margin status was the pathological stage of PCa. Of the patients with positive surgical margins, 26.3% had a pT2 tumor and 73.7% had a pT3 tumor (p=0.001).
Discussion
The clinical impact of VEGF in metastatic PCa has been documented by several studies. Duque et al compared the plasma levels of VEGF-A in 54 patients with localized PCa, 26 patients with metastatic PCa, and 26 controls (4). They found a significant increase in VEGF-A in patients with metastases compared with patients with localized disease and controls. The role of VEGF in metastatic PCa was also suggested by George et al, who found in a series of 197 patients with hormone-refractory PCa that the plasma levels of VEGF-A were independently associated with overall survival (7). The evidence that VEGF plays a significant role in advanced PCa has led to the development of anti-angiogenic therapies. These targeted therapies include bevacizumab, a humanized VEGF-specific monoclonal antibody (8) . Antiangiogenic agents are still under investigation in clinical trials, but in vivo studies have reached promising conclusions (9). Table II . Plasma levels of VEGF-A according to preoperative and postoperative tumor characteristics. 
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Although VEGF plays an important role in metastatic PCa, its impact in localized disease remains to be clarified. Our team has previously analysed the diagnostic value of VEGF for the early detection of PCa (10). We measured VEGF-A in 47 patients who underwent prostate biopsies on clinical and/or biological suspicion of PCa, and found that VEGF was not predictive of cancer on biopsies. This study relied on serum samples. Because VEGF measured in serum may be released from platelets on activation after venipuncture (11), we decided, in the current study, to measure VEGF in plasma.
Shariat et al analysed the plama levels of VEGF-A in 215 patients who underwent RP for clinically-localized PCa, in 9 patients with untreated metastatic PCa, and in 40 controls (5) . In this study, preoperative levels of VEGF-A were significantly elevated in patients with Gleason score ≥7, in patients with extraprostatic stage, and in those with lymph node involvement. Moreover, patients with plasma levels of VEGF-A above the median had an increased risk of biochemical progression after RP. The authors concluded that preoperative levels of VEGF-A could help to predict the tumoral stage and the clinical outcome of patients. The results of our current study gave rise to different conclusions. Such discrepancy may be due to differing methods of VEGF measurement: we used a polyclonal antibody that is designed to measure all the isoforms of VEGF-A, whereas Shariat et al used an immunoassay technique that measures only two isoforms of VEGF-A (VEGF 121 and VEGF 165) (5) .
A surprising finding in our study is that VEGF-A levels were lower in patients with a high Gleason score. However, this result should be considered with caution, owing to the small sample of patients with a high Gleason score. In fact, the vast majority of patients had a Gleason score of 6, and only 6 patients had a Gleason score >7; it is therefore difficult to analyse this parameter.
George et al measured plasma levels of VEGF-A before and after RP in 86 patients with clinically localized PCa (12) . The median reduction in VEGF from before RP to after RP was only 20%. These results suggested that the changes in the post-RP VEGF values could be consistent with a noncancerous source. As was the case in our study, there was no association between plasma levels of VEGF and pre-RP PSA, Gleason score on biopsy, or clinical stage of PCa.
We found that VEGF-A expression was strongly associated with the Gleason score of PCa. This marker could therefore play a prognostic role in localized PCa. To our knowledge, our current study is the first to analyse the prognostic value of VEGF-A expression in PCa. Some previous studies analysed the prognostic value of VEGF-C expression. VEGF-C causes proliferation of lymphatic endothelial cells and plays a role in tumor lymphangiogenesis (1). Li et al compared the expression of VEGF-C receptor (VEGFR-3) in benign prostate hyperplasia and in PCa (13) . These authors found that VEGFR-3 was up-regulated in PCa. Moreover, they found a correlation between VEGFR-3 expression and preoperative PSA, Gleason score and lymph node metastases. Jennbacken et al found a higher expression of VEGF-C in patients with lymph node metastases than in those with localized PCa (14) . Since our current report is the first to analyse the prognostic value of VEGF-A expression in PCa, our results need to be confirmed by further studies.
In our study the clinical outcome of patients was not analysed. Over the last decade, the oncological results of RP Table III . Expression of VEGF-A in PCa tissue according to preoperative and postoperative tumor characteristics. 1 -------------------------------------------------a Fisher's exact test.
-------------------------------------------------have improved markedly, owing to better patient selection and enhanced technique (15) . Furthermore, the interval between treatment and disease recurrence is often longer than two years. To determine whether VEGF-A has an effect on the risk of PCa recurrence and progression, a large cohort of patients with long-term follow-up is mandatory. A major prospective study that will analyse plasma levels of VEGF-A, VEGF-A expression in prostatic tissue, and patient outcome is currently under way in our department.
In summary, we found that plasma levels of VEGF-A were not associated with the established prognostic factors of localized PCa. On the contrary, the expression of VEGF-A in PCa tissue was strongly associated with the Gleason score of cancer. These findings suggest that the expression of VEGF-A in prostate tissue could have a prognostic impact in localized PCa. Because only sparse data are available in the literature, further evaluation of clinical outcome is mandatory to determine the prognostic value of VEGF expression in localized PCa.
